Novo Nordisk Makes Bold $5.2 Billion Move with Akero Buyout to Accelerate Liver Disease Breakthroughs
In a landmark deal marking a new era under CEO Mike Doustdar, Novo Nordisk acquires Akero Therapeutics for up to
Read More
Factual Version of a Story
late-stage drug trials